Cargando…

Bone Marrow and Wharton’s Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy

BACKGROUND: Although cell therapy provides benefits for outcomes of heart failure, the most optimal cell type to be used clinically remains unknown. Most of the cell products used for therapy in humans require in vitro expansion to obtain a suitable number of cells for treatment; however, the clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xian-Liang, Nasr, Marjan, Zheng, Shirong, Zoubul, Taylor, Stephan, Jonah K., Uchida, Shizuka, Singhal, Richa, Khan, Aisha, Gumpert, Anna, Bolli, Roberto, Wysoczynski, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579184/
https://www.ncbi.nlm.nih.gov/pubmed/37500831
http://dx.doi.org/10.1007/s12015-023-10590-6
_version_ 1785121670503071744
author Tang, Xian-Liang
Nasr, Marjan
Zheng, Shirong
Zoubul, Taylor
Stephan, Jonah K.
Uchida, Shizuka
Singhal, Richa
Khan, Aisha
Gumpert, Anna
Bolli, Roberto
Wysoczynski, Marcin
author_facet Tang, Xian-Liang
Nasr, Marjan
Zheng, Shirong
Zoubul, Taylor
Stephan, Jonah K.
Uchida, Shizuka
Singhal, Richa
Khan, Aisha
Gumpert, Anna
Bolli, Roberto
Wysoczynski, Marcin
author_sort Tang, Xian-Liang
collection PubMed
description BACKGROUND: Although cell therapy provides benefits for outcomes of heart failure, the most optimal cell type to be used clinically remains unknown. Most of the cell products used for therapy in humans require in vitro expansion to obtain a suitable number of cells for treatment; however, the clinical background of the donor and limited starting material may result in the impaired proliferative and reparative capacity of the cells expanded in vitro. Wharton’s jelly mesenchymal cells (WJ MSCs) provide a multitude of advantages over adult tissue-derived cell products for therapy. These include large starting tissue material, superior proliferative capacity, and disease-free donors. Thus, WJ MSC if effective would be the most optimal cell source for clinical use. OBJECTIVES: This study evaluated the therapeutic efficacy of Wharton’s jelly (WJ) and bone marrow (BM) mesenchymal stromal cells (MSCs) in chronic ischemic cardiomyopathy in rats. METHODS: Human WJ MSCs and BM MSCs were expanded in vitro, characterized, and evaluated for therapeutic efficacy in a immunodeficient rat model of ischemic cardiomyopathy. Cardiac function was evaluated with hemodynamics and echocardiography. The extent of cardiac fibrosis, hypertrophy, and inflammation was assessed with histological analysis. RESULTS: In vitro analysis revealed that WJ MSCs and BM MSCs are morphologically and immunophenotypically indistinguishable. Nevertheless, the functional analysis showed that WJ MSCs have a superior proliferative capacity, less senescent phenotype, and distinct transcriptomic profile compared to BM MSC. WJ MSCs and BM MSC injected in rat hearts chronically after MI produced a small, but not significant improvement in heart structure and function. Histological analysis showed no difference in the scar size, collagen content, cardiomyocyte cross-sectional area, and immune cell count. CONCLUSIONS: Human WJ and BM MSC have a small but not significant effect on cardiac structure and function when injected intramyocardially in immunodeficient rats chronically after MI. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12015-023-10590-6.
format Online
Article
Text
id pubmed-10579184
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-105791842023-10-18 Bone Marrow and Wharton’s Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy Tang, Xian-Liang Nasr, Marjan Zheng, Shirong Zoubul, Taylor Stephan, Jonah K. Uchida, Shizuka Singhal, Richa Khan, Aisha Gumpert, Anna Bolli, Roberto Wysoczynski, Marcin Stem Cell Rev Rep Article BACKGROUND: Although cell therapy provides benefits for outcomes of heart failure, the most optimal cell type to be used clinically remains unknown. Most of the cell products used for therapy in humans require in vitro expansion to obtain a suitable number of cells for treatment; however, the clinical background of the donor and limited starting material may result in the impaired proliferative and reparative capacity of the cells expanded in vitro. Wharton’s jelly mesenchymal cells (WJ MSCs) provide a multitude of advantages over adult tissue-derived cell products for therapy. These include large starting tissue material, superior proliferative capacity, and disease-free donors. Thus, WJ MSC if effective would be the most optimal cell source for clinical use. OBJECTIVES: This study evaluated the therapeutic efficacy of Wharton’s jelly (WJ) and bone marrow (BM) mesenchymal stromal cells (MSCs) in chronic ischemic cardiomyopathy in rats. METHODS: Human WJ MSCs and BM MSCs were expanded in vitro, characterized, and evaluated for therapeutic efficacy in a immunodeficient rat model of ischemic cardiomyopathy. Cardiac function was evaluated with hemodynamics and echocardiography. The extent of cardiac fibrosis, hypertrophy, and inflammation was assessed with histological analysis. RESULTS: In vitro analysis revealed that WJ MSCs and BM MSCs are morphologically and immunophenotypically indistinguishable. Nevertheless, the functional analysis showed that WJ MSCs have a superior proliferative capacity, less senescent phenotype, and distinct transcriptomic profile compared to BM MSC. WJ MSCs and BM MSC injected in rat hearts chronically after MI produced a small, but not significant improvement in heart structure and function. Histological analysis showed no difference in the scar size, collagen content, cardiomyocyte cross-sectional area, and immune cell count. CONCLUSIONS: Human WJ and BM MSC have a small but not significant effect on cardiac structure and function when injected intramyocardially in immunodeficient rats chronically after MI. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12015-023-10590-6. Springer US 2023-07-28 2023 /pmc/articles/PMC10579184/ /pubmed/37500831 http://dx.doi.org/10.1007/s12015-023-10590-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Tang, Xian-Liang
Nasr, Marjan
Zheng, Shirong
Zoubul, Taylor
Stephan, Jonah K.
Uchida, Shizuka
Singhal, Richa
Khan, Aisha
Gumpert, Anna
Bolli, Roberto
Wysoczynski, Marcin
Bone Marrow and Wharton’s Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy
title Bone Marrow and Wharton’s Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy
title_full Bone Marrow and Wharton’s Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy
title_fullStr Bone Marrow and Wharton’s Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy
title_full_unstemmed Bone Marrow and Wharton’s Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy
title_short Bone Marrow and Wharton’s Jelly Mesenchymal Stromal Cells are Ineffective for Myocardial Repair in an Immunodeficient Rat Model of Chronic Ischemic Cardiomyopathy
title_sort bone marrow and wharton’s jelly mesenchymal stromal cells are ineffective for myocardial repair in an immunodeficient rat model of chronic ischemic cardiomyopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579184/
https://www.ncbi.nlm.nih.gov/pubmed/37500831
http://dx.doi.org/10.1007/s12015-023-10590-6
work_keys_str_mv AT tangxianliang bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT nasrmarjan bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT zhengshirong bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT zoubultaylor bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT stephanjonahk bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT uchidashizuka bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT singhalricha bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT khanaisha bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT gumpertanna bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT bolliroberto bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy
AT wysoczynskimarcin bonemarrowandwhartonsjellymesenchymalstromalcellsareineffectiveformyocardialrepairinanimmunodeficientratmodelofchronicischemiccardiomyopathy